Bone Marrow Transplantation

Fas/FasL Pathway Blockade May Be Beneficial

Published in Blood Weekly, May 17th, 1999

Blockade of the Fas/Fas ligand pathway may be useful in treating graft-versus-host disease without impairing graft-versus-leukemia effect in allogeneic bone marrow transplant recipients.

Allogeneic bone marrow transplantation (allo-BMT) is associated with both graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) effect.

Nobuhiro Tsukada of Japan's Niigata University School of Medicine and colleagues studied the contribution of cytotoxic effector mechanisms, which are mediated by tumor necrosis factor-(alpha) (TNF-(alpha)), Fas ligand (FasL), or perforin, to GVHD and GVL effect in a murine BMT model ("Graft-Versus-Leukemia Effect and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1999-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry